Asset Details
Do you wish to reserve the book?
New addiction to the NRF2‐related factor NRF3 in cancer cells: Ubiquitin‐independent proteolysis through the 20S proteasome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
New addiction to the NRF2‐related factor NRF3 in cancer cells: Ubiquitin‐independent proteolysis through the 20S proteasome
Do you wish to request the book?
New addiction to the NRF2‐related factor NRF3 in cancer cells: Ubiquitin‐independent proteolysis through the 20S proteasome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
New addiction to the NRF2‐related factor NRF3 in cancer cells: Ubiquitin‐independent proteolysis through the 20S proteasome
2020
Overview
Accumulating evidence has revealed that human cancers develop by sequentially mutating pivotal genes, including driver genes, and acquiring cancer hallmarks. For instance, cancer cells are addicted to the transcription factor NRF2 (NFE2L2), which is a driver gene that utilizes the cellular cytoprotection system against oxidative stress and metabolic pathway reprogramming for sustaining high growth. Our group has recently discovered a new addiction to the NRF2‐related factor NRF3 (NFE2L3) in cancer. For many years, the physiological function of NRF3 remained obscure, in part because Nrf3‐deficient mice do not show apparent abnormalities. Nevertheless, human cancer genome databases suggest critical roles of NRF3 in cancer because of high NRF3 mRNA induction in several cancer types, such as colorectal cancer and pancreatic adenocarcinoma, with a poor prognosis. We found that NRF3 promotes tumor growth and malignancy by activating ubiquitin‐independent 20S proteasome assembly through inducing the expression of the proteasome maturation protein (POMP) chaperone and thereby degrading the tumor suppressors p53 and Rb. The NRF3‐POMP‐20S proteasome axis has an entirely different effect on cancer than NRF2. In this review, we describe recent research advances regarding the new cancer effector NRF3, including unclarified ubiquitin‐independent proteolysis by the NRF3‐POMP‐20S proteasome axis. The expected development of cancer therapeutic interventions for this axis is also discussed. Cancer cells hijack cellular systems for sustaining high growth by acquiring gene mutations. For example, they are addicted to the transcription factor NRF2 (NFE2L2). We herein summarize recent research advances regarding the new cancer effector NRF3 (NFE2L3), including unclarified ubiquitin‐independent proteolysis by the NRF3‐POMP‐20S proteasome axis.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
